Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: BCC Research | PRODUCT CODE: 1402418

Cover Image

PUBLISHER: BCC Research | PRODUCT CODE: 1402418

Induced Pluripotent Stem Cells: Global Markets

PUBLISHED:
PAGES: 121 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
PDF & Excel (Single User License)
USD 5500
PDF & Excel (2-5 Users)
USD 6600
PDF & Excel (Site License)
USD 7920
PDF & Excel (Enterprise License)
USD 9504

Add to Cart

Highlights:

The global market for induced pluripotent stem cells (iPSCs) is expected to grow from $3.4 billion in 2023 and forecast to reach $5.2 billion by the end of 2028, at a compound annual growth rate (CAGR) of 9.1% from 2023 through 2028.

The global market for iPSCs generated by non-integrated method is expected to grow from $2.1 billion in 2023 and forecast to reach $3.4 billion by the end of 2028, at a CAGR of 10.1% from 2023 through 2028.

The global market for iPSCs generated by integrated method is expected to grow from $1.3 billion in 2023 and forecast to reach $1.8 billion by the end of 2028, at a CAGR of 7.5% from 2023 through 2028.

Report Scope:

This study focuses on the market side of iPSCs rather than the technical side. Different market segments for this emerging market are covered. For instance, product function-based market segments include molecular and cellular engineering, cellular reprogramming, cell culture, cell differentiation, and cell analysis. Application-based market segments include drug development and toxicity testing, academic research, and regenerative medicine. iPSC-derived cell type-based market segments include hepatocytes, neurons, cardiomyocytes, endothelial cells, and other cell types. Other cell types are comprised of astrocytes, fibroblasts, and hematopoietic and progenitor cells, among other substances. Geographical-based market segments include the U.S., Asia-Pacific, Europe, and the Rest of the World. The research and market trends are also analyzed by studying the funding, patent publications, and research publications in the field.

This report focuses on the market size and segmentation of iPSC products, including iPSC research and clinical products. The market for iPSC-related contract services is also discussed. iPSC research products are defined as all research tools, including iPSCs and various differentiated cells derived from iPSCs, various related assays and kits, culture media and medium components (e.g., serum, growth factors, inhibitors), antibodies, enzymes, and products that can be applied for the specific purpose of executing iPSC research. For this report, iPSC products do not cover stem cell research and clinical products that are broadly applicable to any stem cell type.

This report discusses key manufacturers, technologies, and factors influencing market demand, including the driving forces and limiting factors of the iPSC market's growth. Based on these facts and analysis, the market trends and sales for research and clinical applications are forecast through 2028. One particular focus on the application of iPSCs was given to drug discovery and development, which includes pharmaco-toxicity screening, lead generation, target identification, and other preclinical studies; body-on-a-chip; and 3D disease modeling. Suppliers and manufacturers of iPSC-related products are discussed and analyzed based on their market shares, product types, and geography. An in-depth patent analysis and research funding analysis are also included to assess the overall direction of the iPSC market.

Detailed technologies such as those for generating iPSCs, differentiating iPSCs and controlling the differentiation, and large-scale manufacturing of iPSCs and their derivative cells under Good Manufacturing Practice (GMP) compliance or xeno-free conditions are excluded from the study. They are beyond the scope of this report.

The induced pluripotent stem cell market has been analyzed for four main geographic regions: The U.S., Europe, Asia-Pacific, and the Rest of the World (RoW). The report will provide details with respect to induced pluripotent stem cells.

Report Includes:

  • 34 data tables
  • An overview of the global market for induced pluripotent stem cells (iPSCs)
  • Analysis of global market trends, featuring historical revenue data for 2021 and 2022, estimated figures for 2023, as well as forecasts for 2028, including projections of compound annual growth rates (CAGRs) through 2028
  • Evaluation of the current market size and revenue growth prospects, accompanied by a market share analysis by reprogramming method, method, application, derived tissue cell type, species, product function, end use, and geographic region
  • Analysis of the market's dynamics, including drivers, restraints and opportunities, and the regulatory environments impacting the market
  • Assessment of R&D activity in the iPSC segment, as well as new developments and pipeline products
  • Information on the latest research activities, emerging technologies, and clinical trials
  • Market share analysis of the key companies and coverage of mergers & acquisitions, joint ventures, collaborations, and partnerships
  • Profiles of the major players in the industry
Product Code: BIO135E

Table of Contents

Chapter 1 Introduction

  • Study Goals and Objectives
  • Reasons for Doing This Study
  • Scope of Report
  • What's New in This Update?
  • Methodology
  • Information Sources
  • Geographic Breakdown
  • Segmentation Breakdown

Chapter 2 Summary and Highlights

  • Market Outlook
  • Market Summary

Chapter 3 Market Overview

  • Introduction
  • Pluripotency Factors
  • Research and Therapeutic Significance

Chapter 4 Market Dynamics

  • Market Drivers
  • Growing Research and Development in iPSCs
  • Increased Investment in Biotechnology Industry
  • Rising Prevalence of Chronic Diseases
  • Use of iPSCs in Precision Medicine

Chapter 5 Induced Pluripotent Stem Cell Applications

  • Academic Research
  • Pharmaco-toxicological Screening
  • Drug Discovery and Development
  • Disease Modeling
  • Tissue Engineering
  • Cell Therapy
  • Emerging Technologies

Chapter 6 Induced Pluripotent Stem Cell Market Segmentation and Forecast

  • Market Overview
  • U.S.
  • Europe
  • Asia-Pacific
  • Generation of Induced Pluripotent Stem Cells
  • Application-based Market Overview
  • Induced Pluripotent Stem Cells Product Market
  • Induced Pluripotent Stem Cell-derived Tissue Cell Market
  • Challenges
  • Induced Pluripotent Stem Cells and Their Derivative Cell Market, by Species
  • Global Market
  • Major Suppliers and Manufacturers of Induced Pluripotent Stem Cell Products
  • Market for Induced Pluripotent Stem Cell-derived Cells, by Application
  • Market for Induced Pluripotent Stem Cells, by Product Function
  • Global Market
  • Regional Markets
  • Market for Induced Pluripotent Stem Cells, by End Use

Chapter 7 Induced Pluripotent Stem Cells Research Application Market

  • Induced Pluripotent Stem Cells Research Product Types
  • Major Players
  • Major Commercial Entities
  • Major Noncommercial Organizations
  • Market Shares and Projections

Chapter 8 Induced Pluripotent Stem Cell Contract Service Market

  • Induced Pluripotent Stem Cell Contract Service Types
  • Major Players
  • Market Shares and Projections

Chapter 9 Clinical Application Market Trend Analysis

  • Clinical Trials
  • Age-related Macular Degeneration
  • Ischemic Heart Disease
  • Parkinson's Disease
  • Graft-versus-host Disease (GvHD)
  • Spinal Cord Injuries
  • Corneal Repair
  • Cancer
  • Driving Forces
  • Limiting Factors
  • Technologies
  • Regulations
  • Market Acceptance
  • Clinical Efficiency

Chapter 10 Competitive Landscape

  • Mergers and Acquisitions
  • Strategic Alliances

Chapter 11 Company Profiles

  • ADDGENE
  • ALLELE BIOTECHNOLOGY AND PHARMACEUTICALS INC.
  • ALSTEM
  • APPLIED BIOLOGICAL MATERIALS INC. (ABM)
  • APPLIED STEMCELL INC.
  • ATCC
  • AXOL BIOSCIENCE LTD.
  • BIO-TECHNE CORP.
  • BLUEROCK THERAPEUTICS
  • BRISTOL MYERS SQUIBB (IPIERIAN)
  • CELL SIGNALING TECHNOLOGY (CST)
  • CORNING INC.
  • CREATIVE BIOARRAY‎
  • FATE THERAPEUTICS
  • FUJIFILM CELLULAR DYNAMICS INC. (FCDI)
  • GENECOPOEIA INC.
  • GENTARGET INC.
  • ID PHARMA CO. LTD.
  • INVIVOGEN
  • LONZA GROUP LTD.
  • MEGAKARYON CORP.
  • MERCK KGAA
  • NCARDIA
  • NEWCELLS BIOTECH
  • PEPROTECH INC.
  • PLASTICELL LTD.
  • PROMEGA CORP.
  • PROMOCELL GMBH
  • QIAGEN NV
  • REPROCELL INC.
  • SCIENCELL RESEARCH LABORATORIES
  • STEMCELL TECHNOLOGIES‎
  • SYSTEM BIOSCIENCES INC.
  • TAKARA BIO USA INC. (CLONTECH LABORATORIES)
  • THERMO FISHER SCIENTIFIC
  • VERTEX PHARMACEUTICALS INC.
  • WAISMAN BIOMANUFACTURING

Chapter 12 Appendix: Acronyms

Product Code: BIO135E

List of Tables

  • Summary Table : Global Market for Induced Pluripotent Stem Cells, by Reprogramming Method, Through 2028
  • Table 1 : Global Market for Induced Pluripotent Stem Cells, by Region, Through 2028
  • Table 2 : U.S. Market for Induced Pluripotent Stem Cells, by State, Through 2028
  • Table 3 : European Market for Induced Pluripotent Stem Cells, by Country, Through 2028
  • Table 4 : Asia-Pacific Market for Induced Pluripotent Stem Cells, by Country, Through 2028
  • Table 5 : Global Market for the Generation of Induced Pluripotent Stem Cells, by Reprogramming Method, Through 2028
  • Table 6 : Global Market for Induced Pluripotent Stem Cells, by Method, Through 2028
  • Table 7 : Global Market for Induced Pluripotent Stem Cell Products, by Application, Through 2028
  • Table 8 : U.S. Market for Induced Pluripotent Stem Cell Products, by Application, Through 2028
  • Table 9 : European Market for Induced Pluripotent Stem Cell Products, by Application, Through 2028
  • Table 10 : Asia-Pacific Market for Induced Pluripotent Stem Cell Products, by Application, Through 2028
  • Table 11 : Rest of the World Market for Induced Pluripotent Stem Cell Products, by Application, Through 2028
  • Table 12 : Global Market for Induced Pluripotent Stem Cell-derived Tissue Cells, by Type, Through 2028
  • Table 13 : Global Market for Induced Pluripotent Stem Cell-derived Cells, by Species, Through 2028
  • Table 14 : Major Commercial Suppliers of Induced Pluripotent Stem Cell Products, by Country
  • Table 15 : Major Commercial Manufacturers of Induced Pluripotent Stem Cells, by Country
  • Table 16 : Global Market for Induced Pluripotent Stem Cell-derived Cells, by Application, Through 2028
  • Table 17 : Global Market for Induced Pluripotent Stem Cell-related Products, by Product Function, Through 2028
  • Table 18 : U.S. Market for Induced Pluripotent Stem Cell-related Products, by Product Function, Through 2028
  • Table 19 : European Market for Induced Pluripotent Stem Cell-related Products, by Product Function, Through 2028
  • Table 20 : Asia-Pacific Market for Induced Pluripotent Stem Cell-related Products, by Product Function, Through 2028
  • Table 21 : RoW Market for Induced Pluripotent Stem Cell-related Products, by Product Function, Through 2028
  • Table 22 : Global Market for Induced Pluripotent Stem Cells, by End Use, Through 2028
  • Table 23 : Global Market for Induced Pluripotent Stem Cell-related Products, by Function, Through 2028
  • Table 24 : Major University and Institute Facilities for Induced Pluripotent Stem Cell Research, by Location/Country
  • Table 25 : Major Companies Providing iPSC Contract Services, by State/Country
  • Table 26 : Global Market for Induced Pluripotent Stem Cell Contract Services, by Region, Through 2028
  • Table 27 : Induced Pluripotent Stem Cells Pipeline (Interventional Trials)*
  • Table 28 : Bio-Techne: Annual Financials/Revenue, 2022
  • Table 29 : Bristol Myers Squibb: Financials/Revenue, 2022
  • Table 30 : Corning Inc.: Financials/Revenue, 2022
  • Table 31 : Qiagen NV: Annual Financials/Revenue, 2022
  • Table 32 : Thermo Fisher Scientific: Annual Financials/Revenue, 2022
  • Table 33 : Acronyms Used in the iPSCs Industry

List of Figures

  • Summary Figure : Global Market for Induced Pluripotent Stem Cells, by Reprogramming Method, 2021-2028
  • Figure 1 : Global Market Share of Induced Pluripotent Stem Cells, by Region, 2022
  • Figure 2 : U.S. Market Share of Induced Pluripotent Stem Cells, by State, 2022
  • Figure 3 : European Market Share of Induced Pluripotent Stem Cells, by Country, 2028
  • Figure 4 : Asia-Pacific Market Share of Induced Pluripotent Stem Cells, by Country, 2022
  • Figure 5 : Global Market Share of Induced Pluripotent Stem Cells, by Reprogramming Method, 2022
  • Figure 6 : Global Market Share of Induced Pluripotent Stem Cells, by Method, 2022
  • Figure 7 : Global Market Share of Induced Pluripotent Stem Cell Products, by Application, 2022
  • Figure 8 : U.S. Market Share of Induced Pluripotent Stem Cell Products, by Application, 2022
  • Figure 9 : European Market Share of Induced Pluripotent Stem Cell Products, by Application, 2022
  • Figure 10 : Asia-Pacific Market Share of Induced Pluripotent Stem Cell Products, by Application, 2022
  • Figure 11 : Rest of the World Market Share of Induced Pluripotent Stem Cell Products, by Application, 2022
  • Figure 12 : Global Market Share of Induced Pluripotent Stem Cell-derived Tissue Cells, by Type, 2022
  • Figure 13 : Global Market Share of Induced Pluripotent Stem Cell-derived Cells, by Application, 2022
  • Figure 14 : Global Market Share of Induced Pluripotent Stem Cell-related Products, by Product Function, 2022
  • Figure 15 : U.S. Market Share of Induced Pluripotent Stem Cell-related Products, by Product Function, 2022
  • Figure 16 : European Market Share of Induced Pluripotent Stem Cell-related Products, by Product Function, 2022
  • Figure 17 : Asia-Pacific Market Share of Induced Pluripotent Stem Cell-related Products, by Product Function, 2022
  • Figure 18 : RoW Market Share of Induced Pluripotent Stem Cell-related Products, by Product Function, 2022
  • Figure 19 : Global Market Share of Induced Pluripotent Stem Cells, by End Use, 2022
  • Figure 20 : Global Market Share of Induced Pluripotent Stem Cell-related Products, by Function, 2022
  • Figure 21 : Global Market Share of Induced Pluripotent Stem Cell Contract Services, by Region, 2022
  • Figure 22 : Clinical-trial Analysis: Induced Pluripotent Stem Cells
  • Figure 23 : Bio-Techne: Annual Financials/Revenue, 2021 and 2022
  • Figure 24 : Bio-Techne: Revenue Share, by Country/Region, 2022
  • Figure 25 : Bio-Techne: Revenue Share, by Business Segment, 2022
  • Figure 26 : Bristol Myers Squibb: Financials/Revenue, 2021 and 2022
  • Figure 27 : Bristol Myers Squibb: Revenue Share, by Business Unit, 2022
  • Figure 28 : Bristol Myers Squibb: Revenue Share, by Country/Region, 2022
  • Figure 29 : Corning Inc.: Financials/Revenue, 2021 and 2022
  • Figure 30 : Corning Inc.: Revenue Share, by Business Segment, 2022
  • Figure 31 : Qiagen NV: Annual Financials/Revenue, 2021 and 2022
  • Figure 32 : Qiagen NV: Revenue Share, by Business Unit, 2022
  • Figure 33 : Qiagen NV: Revenue Share, by Region, 2022
  • Figure 34 : Thermo Fisher Scientific: Annual Financials/Revenue, 2021 and 2022
  • Figure 35 : Thermo Fisher Scientific: Revenue Share, by Business Unit, 2022
  • Figure 36 : Thermo Fisher Scientific: Revenue Share, by Region, 2022
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!